OncoSec Medical Inc (ONCSQ)

[hschlauch]

IDO1 inhibitors will always fail in patients who are not already primed. If there is no interferon gamma production to begin with, then there is not going to be much upregulation of IDO. It is like using a PD-1 antagonist in patients who don't have high percentages of PD-1 expressing CTLs at baseline. So many of these combination immunotherapies aren't going to make much of a difference if they don't address the priming phase in the immune cycle.

Timing is everything, and this really holds true with IDO1 inhibitors.